Rabelock lyophilisate solution 20mg vials, 1pc

Composition

Active ingredient:

rabeprazole sodium 20 mg;

Excipients:

mannitol 75 mg,

sodium hydroxide up to pH 11.0.

Pharmacological action

Rabeloc is an anti-ulcer agent, an inhibitor of H+ – K+ – ATPASE (proton pump).

The mechanism of action is associated with the inhibition of the enzyme H+-K+-ATPASE in the parietal cells of the stomach, which leads to blocking the final stage of formation of hydrochloric acid.

This effect is dose-dependent and leads to inhibition of both basal and stimulated hydrochloric acid secretion, regardless of the nature of the stimulus.

Indications

• Peptic ulcer of the stomach and duodenum in the acute phase;
• peptic ulcer of the stomach and duodenum associated with Helicobacter pylori (in combination with antibiotics);
• gastroesophageal reflux.

Use during pregnancy and lactation

Rabeprazole is contraindicated for use during pregnancy and lactation.

In experimental studies, it was found that rabeprazole in small amounts penetrates the placental barrier, but there were no violations of fertility or defects in fetal development; it is excreted in the milk of lactating rats.

There is no clinical experience of using rabeprazole in children, so its use is not recommended.

Contraindications

Pregnancy, lactation (breast-feeding), hypersensitivity to rabeprazole sodium or substituted benzimidazoles.

Side effects

From the digestive system:  diarrhea, nausea, abdominal pain, vomiting, flatulence, constipation; rarely-dry mouth, dyspepsia, belching; in rare cases – anorexia, gastritis, stomatitis, increased activity of hepatic transaminases.

From the central nervous system and peripheral nervous system:  headache, asthenia, dizziness, insomnia; rarely-nervousness, drowsiness; in isolated cases-depression, visual disturbances and taste sensations.

Respiratory system disorders:  possible – rhinitis, pharyngitis, cough; rarely-sinusitis, bronchitis.

Allergic reactions:  rarely-skin rash; in isolated cases-itching.

Other services:  back pain, flu-like syndrome; rarely-myalgia, chest pain, chills, calf muscle cramps, urinary tract infection, arthralgia, fever; in rare cases-weight gain, increased sweating, leukocytosis.

Interaction

When used concomitantly with digoxin, it is possible to increase (from small to moderate) the concentration of digoxin in blood plasma.

When used concomitantly with ketoconazole, its bioavailability decreases.

How to take, course of use and dosage

They are taken orally. A single dose is 10-20 mg. The frequency and duration of use depend on the indications and treatment regimen.

Special instructions

Before starting therapy, it is necessary to exclude malignant neoplasms of the stomach, since the use of rabeprazole can mask the symptoms and delay the correct diagnosis.

Patients with impaired liver or kidney function do not need to adjust the dose, but in patients with severe hepatic impairment, rabeprazole is recommended to be used with caution.

When used concomitantly with rabeprazole, the dose of ketoconazole and digoxin should be adjusted.

In experimental studies, the carcinogenic effect of rabeprazole was not established, however, when studying mutagenicity, ambiguous results were obtained. Tests on mouse lymphoma cells were positive, while the in vivo micronucleus test and the in vivo and in vitro DNA repair tests were negative.

Form of production

Lyophilizate for the preparation of a solution for intravenous use

Storage conditions

In a dark place, at a temperature not exceeding 25 °C.

Shelf life

2 years

Active ingredient

Rabeprazole

Conditions of release from pharmacies

By prescription

Dosage form

infusion solution